Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.19.3
Commitments and Contingencies (Details Narrative)
1 Months Ended 9 Months Ended
Nov. 30, 2017
USD ($)
Nov. 30, 2016
USD ($)
ft²
Sep. 30, 2019
USD ($)
Monthly lease payments     $ 149,101
Alachua Facility [Member]      
Period of lease     5 years
Amendment Alachua Facility [Member]      
Period of lease     5 years
Tampa Facility [Member]      
Period of lease   36 months  
Area of office space leased | ft²   2,207  
Lease expiry date   Feb. 29, 2020  
Maximum [Member] | Alachua Facility [Member]      
Monthly lease payments     $ 10,851
Maximum [Member] | Amendment Alachua Facility [Member]      
Monthly lease payments     13,338
Maximum [Member] | Tampa Facility [Member]      
Monthly lease payments   $ 4,392  
Minimum [Member] | Alachua Facility [Member]      
Monthly lease payments     9,641
Minimum [Member] | Amendment Alachua Facility [Member]      
Monthly lease payments     $ 12,870
Minimum [Member] | Tampa Facility [Member]      
Monthly lease payments   $ 4,138  
Lantibiotic Exclusive Channel Collaboration [Member] | Intrexon [Member] | Cost Of Revenue [Member]      
Royalty payment percentage     25.00%
Lantibiotic Exclusive Channel Collaboration [Member] | Prior to Amendment [Member]      
Royalty payment of sublicenses percentage 50.00%    
Lantibiotic Exclusive Channel Collaboration [Member] | Prior to Amendment [Member] | Product Profit [Member]      
Reduction in royalty rate percentage 25.00%    
Lantibiotic Exclusive Channel Collaboration [Member] | Subsequent to Amendment [Member]      
Royalty payment of sublicenses percentage 25.00%    
Amount required to expended for advancement of lantibiotic program $ 1,200,000    
Lantibiotic Exclusive Channel Collaboration [Member] | Subsequent to Amendment [Member] | Net Sales [Member]      
Reduction in royalty rate percentage 10.00%    
Lantibiotic Exclusive Channel Collaboration [Member] | Amendment [Member] | Intrexon [Member] | Net Sales [Member]      
Royalty payment percentage     10.00%
Lantibiotic Exclusive Channel Collaboration [Member] | New Drug Application [Member]      
Milestone payment under licensing agreement $ 25,000,000    
Milestone measurement period 6 years    
Lantibiotic Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member]      
Milestone payment under licensing agreement     $ 25,000,000
Milestone measurement period     6 months
Lantibiotic Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member]      
Milestone payment under licensing agreement     $ 5,000,000
Milestone measurement period     6 months
Lantibiotic Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member]      
Milestone payment under licensing agreement     $ 5,000,000
Milestone measurement period     6 months
Oral Mucositis Exclusive Channel Collaboration [Member] | Maximum [Member]      
Royalty payment of sublicenses percentage 50.00%    
Maturity of interest bearing promissory note     12 months
Oral Mucositis Exclusive Channel Collaboration [Member] | Minimum [Member]      
Royalty payment of sublicenses percentage 25.00%    
Oral Mucositis Exclusive Channel Collaboration [Member] | Intrexon [Member] | Net Sales [Member]      
Royalty payment percentage     12.00%
Oral Mucositis Exclusive Channel Collaboration [Member] | Intrexon [Member] | Cost Of Revenue [Member]      
Royalty payment percentage     25.00%
Oral Mucositis Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member]      
Milestone payment under licensing agreement     $ 27,500,000
Milestone measurement period     6 months
Oral Mucositis Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member]      
Milestone payment under licensing agreement     $ 5,000,000
Milestone measurement period     6 months
Oral Mucositis Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member]      
Milestone payment under licensing agreement     $ 5,000,000
Milestone measurement period     6 months
Oral Mucositis Exclusive Channel Collaboration [Member] | New Product Application [Member]      
Milestone payment under licensing agreement $ 27,500,000    
Milestone measurement period 6 years